Monocytic Ontogeny of Regenerated Macrophages Characterizes the Mesotheliomagenic Responses to Carbon Nanotubes.

Animals Cell Differentiation Cell Proliferation Histocompatibility Antigens Class II / metabolism Inflammation Macrophages / cytology Mesothelioma / chemically induced Monocytes / cytology Nanotubes, Carbon / adverse effects Neutrophils / cytology Peritoneal Cavity / cytology Rats
inflammation macrophage niche macrophage origin macrophage proliferation mesothelioma monocytes peritoneal macrophages

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 26 02 2021
accepted: 28 05 2021
entrez: 1 7 2021
pubmed: 2 7 2021
medline: 15 10 2021
Statut: epublish

Résumé

Macrophages are not only derived from circulating blood monocytes or embryonic precursors but also expand by proliferation. The origin determines macrophage fate and functions in steady state and pathological conditions. Macrophages predominantly infiltrate fibre-induced mesothelioma tumors and contribute to cancer development. Here, we revealed their ontogeny by comparing the response to needle-like mesotheliomagenic carbon nanotubes (CNT-7) with tangled-like non-mesotheliomagenic CNT-T. In a rat peritoneal cavity model of mesothelioma, both CNT induced a rapid macrophage disappearance reaction (MDR) of MHCII

Identifiants

DOI: 10.3389/fimmu.2021.666107 PMID: 34194430 PMC: PMC8236701
pubmed: 34194430
doi: 10.3389/fimmu.2021.666107
pmc: PMC8236701
doi:

Substances chimiques

Histocompatibility Antigens Class II 0
Nanotubes, Carbon 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

666107

Informations de copyright

Copyright © 2021 Orsi, Palmai-Pallag, Yakoub, Ibouraadaten, De Beukelaer, Bouzin, Bearzatto, Ambroise, Gala, Brusa, Lison and Huaux.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Exp Med. 2009 Apr 13;206(4):937-52
pubmed: 19349464
Innate Immun. 2016 Jul;22(5):382-92
pubmed: 27220602
Sci Rep. 2018 Oct 12;8(1):15180
pubmed: 30315271
Orphanet J Rare Dis. 2008 Dec 19;3:34
pubmed: 19099560
Front Immunol. 2020 Jun 17;11:1060
pubmed: 32625201
Trends Immunol. 2017 Jul;38(7):526-536
pubmed: 28579319
Inhal Toxicol. 2002 Jul;14(7):685-703
pubmed: 12122570
J Exp Med. 2018 Mar 5;215(3):859-876
pubmed: 29436396
Nat Nanotechnol. 2020 Mar;15(3):164-166
pubmed: 32157238
J Immunol. 2013 Nov 1;191(9):4665-75
pubmed: 24078688
Immunity. 2019 Oct 15;51(4):638-654.e9
pubmed: 31561945
Immunity. 2016 Mar 15;44(3):439-449
pubmed: 26982352
Science. 2013 Feb 1;339(6119):535-9
pubmed: 23372006
Toxicol Sci. 2009 Aug;110(2):442-8
pubmed: 19429663
Nucleic Acids Res. 2019 Jan 8;47(D1):D745-D751
pubmed: 30407521
Oncotarget. 2016 May 10;7(19):28697-710
pubmed: 26885690
Nat Nanotechnol. 2008 Jul;3(7):423-8
pubmed: 18654567
PLoS Comput Biol. 2020 Feb 25;16(2):e1007664
pubmed: 32097405
Nanotoxicology. 2013 Sep;7(6):1157-67
pubmed: 22812632
Nat Rev Immunol. 2017 Jul;17(7):451-460
pubmed: 28461703
Cancer Immunol Res. 2017 Jul;5(7):535-546
pubmed: 28536100
J Toxicol Sci. 2018;43(10):587-600
pubmed: 30298847
FEBS J. 2018 Feb;285(4):680-699
pubmed: 29171156
Pathol Int. 2013 Sep;63(9):457-62
pubmed: 24200157
Front Oncol. 2019 Dec 06;9:1366
pubmed: 31867277
J Exp Med. 2019 Jun 3;216(6):1291-1300
pubmed: 31048328
Cell. 2016 Apr 21;165(3):668-78
pubmed: 27062926
Front Immunol. 2015 May 19;6:225
pubmed: 26042120
Part Fibre Toxicol. 2016 Aug 12;13(1):40
pubmed: 27519871
Immunity. 2020 Mar 17;52(3):434-451
pubmed: 32187515
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Part Fibre Toxicol. 2016 Aug 23;13(1):46
pubmed: 27549627
Nanotoxicology. 2019 Nov;13(9):1244-1274
pubmed: 31537143
Sci Rep. 2018 Jan 18;8(1):1115
pubmed: 29348435
J Vis Exp. 2015 Apr 01;(98):e52553
pubmed: 25867947
Cell Immunol. 2018 Aug;330:126-135
pubmed: 29397065
G3 (Bethesda). 2019 Jul 9;9(7):2089-2096
pubmed: 31088905
Part Fibre Toxicol. 2014 Nov 20;11:59
pubmed: 25410479
Nat Commun. 2021 Mar 19;12(1):1770
pubmed: 33741914
J Exp Med. 2016 Sep 19;213(10):1951-9
pubmed: 27551152
Nanotoxicology. 2015;9(5):658-76
pubmed: 25676622
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Am J Respir Cell Mol Biol. 2011 Feb;44(2):230-7
pubmed: 20395632
Nanomaterials (Basel). 2020 Feb 04;10(2):
pubmed: 32033249
Cell. 2014 May 8;157(4):832-44
pubmed: 24792964

Auteurs

Micaela Orsi (M)

Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Mihaly Palmai-Pallag (M)

Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Yousof Yakoub (Y)

Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Saloua Ibouraadaten (S)

Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Michèle De Beukelaer (M)

Imaging Platform, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Caroline Bouzin (C)

Imaging Platform, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Bertrand Bearzatto (B)

Center for Applied Molecular Technologies, Institute of Experimental and Clinical Research (IREC), Cliniques Universitaires Saint-Luc and Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Jérôme Ambroise (J)

Center for Applied Molecular Technologies, Institute of Experimental and Clinical Research (IREC), Cliniques Universitaires Saint-Luc and Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Jean-Luc Gala (JL)

Center for Applied Molecular Technologies, Institute of Experimental and Clinical Research (IREC), Cliniques Universitaires Saint-Luc and Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Davide Brusa (D)

Flow Cytometry Platform, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Dominique Lison (D)

Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

François Huaux (F)

Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

Within-subject variation of C-reactive protein and high-sensitivity C-reactive protein: A systematic review and meta-analysis.

Alex Gough, Alice Sitch, Erica Ferris et al.
1.00
C-Reactive Protein Humans Biomarkers Inflammation

Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis.

Yanhui Yang, Ji Li, Yi Wang et al.
1.00
Humans Immune Checkpoint Inhibitors Lung Neoplasms Prognosis Inflammation

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Monocytic Ontogeny of Regenerated Macrophages...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Différenciation cellulaire › Monocytic Ontogeny of Regenerated Macrophages...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Monocytic Ontogeny of Regenerated Macrophages...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes d'histocompatibilité de classe II › Monocytic Ontogeny of Regenerated Macrophages...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Monocytic Ontogeny of Regenerated Macrophages...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Macrophages › Monocytic Ontogeny of Regenerated Macrophages...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Tumeurs mésotheliales › Mésothéliome › Monocytic Ontogeny of Regenerated Macrophages...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Monocytes › Monocytic Ontogeny of Regenerated Macrophages...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanotubes › Nanotubes de carbone › Monocytic Ontogeny of Regenerated Macrophages...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Granulocytes neutrophiles › Monocytic Ontogeny of Regenerated Macrophages...
questionsmedicales.fr › Régions du corps › Tronc › Abdomen › Cavité abdominale › Cavité péritonéale › Monocytic Ontogeny of Regenerated Macrophages...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Monocytic Ontogeny of Regenerated Macrophages...